CTOs on the Move

Allogene

www.allogene.com

 
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient`s own cells, simplifies manufacturing, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.allogene.com
  • 270 Littlefield Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.457.2700

Executives

Name Title Contact Details
Nancy Saputra
 IT Director, Systems, Cloud, and Information Security Profile
Timothy Moore
 Chief Technical Officer Profile
Timothy Moore
 Chief Technology Officer Profile
Alison Moore
 Chief Technical Officer Profile
Alison Moore
 Executive Vice President of Operations and Chief Technical Officer Profile

Funding

Allogene raised $300M on 04/03/2018
Allogene raised $411.8M on 04/19/2018
Allogene raised $120M on 09/07/2018

Similar Companies

Provivi

We are a groundbreaking science-based company creating scalable, safer insect control technology that will improve the quality of life for all humans and our world.

ROME Therapeutics

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.”

Isis Pharmaceuticals Inc

Isis Pharmaceuticals Inc is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Denali Therapeutics

Denali Therapeutics Inc. (“Denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).

miR Scientific

miR’s Disease Management Platform™ gives providers and patients first-time access to actionable health data, illuminating a clear path to cancer management.